Nano-X Imaging Ltd. (NASDAQ: NNOX) (“Nanox”) is advancing Nanox.AI’s commercial and technology strategy through two developments aimed at expanding the use of AI in medical imaging, according to a recent announcement. The first is an exclusive three-year reseller agreement with Vertec Scientific, including minimum annual license commitments, which establishes a dedicated UK channel for HealthOST, an AI-powered software solution that delivers qualitative and quantitative analysis of spinal CT images to help clinicians evaluate and assess spinal musculoskeletal disease, including osteoporosis. The second is that Nanox.AI has optimized its imaging AI framework for Intel Core Ultra processors using OpenVINO, demonstrating the potential to run AI inference locally on hospital hardware and reduce reliance on cloud connectivity.
Together, these developments support Nanox.AI’s strategy of extracting additional clinical value from already performed scans while expanding commercial reach and offering healthcare providers more flexible deployment options. The UK reseller agreement with Vertec Scientific provides a direct route to market for HealthOST, which could lead to earlier detection and better management of spinal conditions like osteoporosis. Osteoporosis is a common condition, particularly among older adults, and often goes undiagnosed until a fracture occurs. By enabling clinicians to analyze existing CT scans for signs of spinal musculoskeletal disease, HealthOST may help identify at-risk patients without additional imaging procedures.
The optimization for Intel Core Ultra processors with OpenVINO is equally significant. Running AI inference locally on hospital hardware could reduce dependence on cloud connectivity, addressing concerns about data latency, bandwidth, and privacy. It may also lower costs associated with cloud computing and make AI tools more accessible to hospitals with limited internet infrastructure. This aligns with Nanox’s broader mission to drive the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform.
Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care. The Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provides access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT, which combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery. For more information, please visit www.Nanox.vision.
The latest news and updates relating to NNOX are available in the company’s newsroom at https://ibn.fm/NNOX. The announcement was covered by BioMedWire, a specialized communications platform focused on the latest developments in the Biotechnology, Biomedical Sciences and Life Sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. The platform also offers article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, and social media distribution via IBN to millions of social media followers. For more information, please visit www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
